Niels Jonas Heilskov Graversen
Directeur Général chez Affinicon ApS
Profil
Niels Jonas Heilskov Graversen founded Proteopharma AS in 2000, where he worked as Principal, Cytoguide ApS in 2007, where he worked as Chief Scientific Officer from 2007 to 2014, Affinicon ApS in 2013, where he is working as Chief Executive Officer from 2013, and DeLiver Pharma ApS in 2018, where he is working as Chief Executive Officer & Director from 2018.
Dr. Graversen also formerly worked at Novo Nordisk A, as Principal, Borean Pharma ApS, as Principal, and Symphogen A, as Principal.
Dr. Graversen received his graduate degree in 1997 from the University of Aarhus and doctorate degree in 2000 from the University of Aarhus.
Postes actifs de Niels Jonas Heilskov Graversen
| Sociétés | Poste | Début |
|---|---|---|
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Directeur Général | 04/07/2013 |
DeLiver Pharma ApS
 DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Fondateur | 09/03/2018 |
Anciens postes connus de Niels Jonas Heilskov Graversen
| Sociétés | Poste | Fin |
|---|---|---|
Cytoguide ApS
 Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Fondateur | 20/05/2014 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Borean Pharma ApS provides biopharmaceuticals drugs and protein engineering services. Its two main components of technology platform are CTLD library technology and trimerisation technology. The company was founded by Hans Christian Thøgersen and Michael Etzerodt in 1997 and is located in Aarhus, Denmark. | Corporate Officer/Principal | - |
Proteopharma AS
 Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Fondateur | - |
Formation de Niels Jonas Heilskov Graversen
| University of Aarhus | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Entreprise privées | 6 |
|---|---|
Borean Pharma ApS
Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Borean Pharma ApS provides biopharmaceuticals drugs and protein engineering services. Its two main components of technology platform are CTLD library technology and trimerisation technology. The company was founded by Hans Christian Thøgersen and Michael Etzerodt in 1997 and is located in Aarhus, Denmark. | Health Technology |
Proteopharma AS
Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
DeLiver Pharma ApS
DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Health Technology |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |